chronic myeloid leukemia. Chronic myeloid leukemia, BCR/ABL-positive
Conditions
Interventions
Intervention 1: Intervention group: Chronic myeloid leukemia patients treated with nilotinib and dasatinib undergoing carvedilol intervention. Intervention 2: Control group: Chronic myeloid leukemia p
Sponsors
Mazandaran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients with chronic myeloid leukemia treated with nilotinib and dasatinib for at least one year Age>18 Sinus rhythm of the heart
Exclusion criteria
Exclusion criteria: Acute and Chronic Heart Failure Low Ejection Fraction History of valvular heart disease or congenital heart disease Systolic blood pressure <90 mm Hg or diastolic blood pressure <60 mm Hg PR interval = 240 ms AV block grade 2-3 History of Asthema Chronic Obsteractive Pulmonary Disease Previous medical history of cardioprotective drugs (such as ACE inhibitors or dexrazoxane) Previous diagnosis of cardiomyopathy, history of coronary artery disease, moderate to severe mitral and aortic disease, and atrial fibrillation. Lack of consent to participate in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Study of the effect of carvedilol on cardiac function in patients with chronic myeloid leukemia treated with nilotinib and dasatinib in Sari city. Timepoint: Outcomes are measured at 0, 6, and 12 months. Method of measurement: Based on echocardiography by an echocardiogram specialist and measurement of cardiac-specific biomarkers ProBNP, Troponin I. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAli Bazram
Mazandaran University of Medical Sciences
Outcome results
None listed